| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
2,250,000,000 |
| Market
Cap: |
100.60(B) |
| Last
Volume: |
14,535,649 |
Avg
Vol: |
11,963,293 |
| 52
Week Range: |
$43.67 - $69.08 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 100 |
|
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 11.3 |
| Insider 3/6 Months : 11.9 |
|
| Guru Rank Number : 97 |
| Guru Rank Value : 8.6 |
| Guru Occurances : 3 |
|
|
|
|
|
| |
|
Company Profile Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Co.'s primary products include: Revlimid®, in which Revlimid (lenalidomide) is an oral immunomodulatory drug that in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma; and Eliquis®, in which Eliquis (apixaban) is an oral Factor Xa inhibitor indicated for the reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE and reduction in risk of recurrence following initial therapy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
13,571 |
13,571 |
13,571 |
| Total Buy Value |
$0 |
$672,994 |
$672,994 |
$672,994 |
| Total People Bought |
0 |
2 |
2 |
2 |
| Total Buy Transactions |
0 |
3 |
3 |
3 |
| Total Shares Sold |
0 |
0 |
18,718 |
681,397 |
| Total Sell Value |
$0 |
$0 |
$1,146,397 |
$49,727,684 |
| Total People Sold |
0 |
0 |
2 |
6 |
| Total Sell Transactions |
0 |
0 |
2 |
12 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ahmed Nadim |
President, Hematology |
• – – |
2020-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
17,204 |
33,028 |
|
- |
|
| Ahmed Nadim |
President, Hematology |
• – – |
2020-02-04 |
4 |
D |
$64.29 |
$68,855 |
D/D |
(1,071) |
15,824 |
|
- |
|
| Ahmed Nadim |
President, Hematology |
• – – |
2020-02-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,076 |
16,895 |
|
- |
|
| Vessey Rupert |
Pres., Research & Early Dev. |
• – – |
2020-02-04 |
4 |
D |
$64.29 |
$74,769 |
D/D |
(1,163) |
24,757 |
|
- |
|
| Vessey Rupert |
Pres., Research & Early Dev. |
• – – |
2020-02-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,592 |
25,920 |
|
- |
|
| Elkins David V |
EVP, Chief Financial Officer |
• – – |
2019-12-31 |
4 |
D |
$64.19 |
$391,174 |
D/D |
(6,094) |
20,187 |
|
- |
|
| Elkins David V |
EVP, Chief Financial Officer |
• – – |
2019-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,373 |
26,281 |
|
- |
|
| Vessey Rupert |
Pres., Research & Early Dev. |
• – – |
2019-12-31 |
4 |
D |
$64.19 |
$507,743 |
D/D |
(7,910) |
22,868 |
|
- |
|
| Vessey Rupert |
Pres., Research & Early Dev. |
• – – |
2019-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,060 |
30,778 |
|
- |
|
| Dubow Adam |
Chief Compliance & Ethics Offi |
• – – |
2019-12-05 |
4 |
S |
$58.81 |
$102,329 |
D/D |
(1,740) |
15,749 |
|
- |
|
| Bonney Michael W |
Director |
– • – |
2019-12-04 |
4 |
B |
$58.90 |
$5,183 |
D/D |
88 |
7,189 |
2.39 |
- |
|
| Eid Joseph |
SVP,Head Glob. Medical Affairs |
• – – |
2019-12-01 |
4/A |
D |
$56.94 |
$55,118 |
D/D |
(968) |
5,327 |
|
- |
|
| Eid Joseph |
SVP,Head Glob. Medical Affairs |
• – – |
2019-12-01 |
4/A |
OE |
$0.00 |
$0 |
D/D |
2,825 |
6,295 |
|
- |
|
| Eid Joseph |
SVPHead Global Medical Affairs |
• – – |
2019-12-01 |
4 |
D |
$56.94 |
$55,118 |
D/D |
(968) |
4,027 |
|
- |
|
| Eid Joseph |
SVPHead Global Medical Affairs |
• – – |
2019-12-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,825 |
4,995 |
|
- |
|
| Bonney Michael W |
Director |
– • – |
2019-11-20 |
3/A |
IO |
$0.00 |
$0 |
I/I |
0 |
2,000 |
|
- |
|
| Bonney Michael W |
Director |
– • – |
2019-11-20 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
7,189 |
|
- |
|
| Vessey Rupert |
Pres., Research & Early Dev. |
• – – |
2019-11-20 |
4 |
A |
$0.00 |
$0 |
I/I |
613 |
613 |
|
- |
|
| Vessey Rupert |
Pres., Research & Early Dev. |
• – – |
2019-11-20 |
4 |
A |
$0.00 |
$0 |
D/D |
14,178 |
14,178 |
|
- |
|
| Ahmed Nadim |
President, Hematology |
• – – |
2019-11-20 |
4 |
A |
$0.00 |
$0 |
I/I |
1,966 |
1,966 |
|
- |
|
| Ahmed Nadim |
President, Hematology |
• – – |
2019-11-20 |
4 |
A |
$0.00 |
$0 |
D/D |
14,819 |
14,819 |
|
- |
|
| Elkins David V |
EVP, Chief Financial Officer |
• – – |
2019-11-20 |
4 |
A |
$0.00 |
$0 |
I/I |
195 |
195 |
|
- |
|
| Elkins David V |
EVP, Chief Financial Officer |
• – – |
2019-11-20 |
4 |
A |
$0.00 |
$0 |
D/D |
13,908 |
13,908 |
|
- |
|
| Schmukler Louis S |
Pres., Global Mfg. & Supply |
• – – |
2019-11-05 |
4 |
S |
$56.56 |
$1,414,000 |
D/D |
(25,000) |
31,963 |
|
- |
|
| Elicker John E |
SVP, Public Affairs & IR |
• – – |
2019-11-05 |
4 |
S |
$56.66 |
$849,900 |
D/D |
(15,000) |
74,471 |
|
- |
|
2225 Records found
|
|
Page 16 of 89 |
|
|
0.35 (0.78%) 
